SCHEMBL2010639

SCHEMBL2010639

CC(=O)CC(C(=O)O)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.53
ALDH1A1 P00352 3/20 0.53
LMNA P02545 1/20 0.38
SLC15A2 Q16348 1/20 0.38
FFAR3 O14843 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
GRIK1 P39086 1/20 0.37
TP53 P04637 1/20 0.37
TRPA1 O75762 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CHRM1 P11229 1/20 0.35
AKR1A1 P14550 1/20 0.35
CHRM3 P20309 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
ADRA1A P35348 1/20 0.35
HRH1 P35367 1/20 0.35
DRD3 P35462 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11309347 0.88 TDP1 (0.48) TDP1ALDH1A1LMNASLC15A2FFAR3
SCHEMBL27602519 0.83 TDP1 (0.43) TDP1ALDH1A1LMNASLC15A2GRIK1
SCHEMBL233057 0.80 ALDH1A1 (0.53) TDP1ALDH1A1LMNASLC15A2TRPA1
SCHEMBL10455829 0.79 ALDH1A1 (0.40) TDP1ALDH1A1GRIK1
SCHEMBL17637932 0.78 TDP1 (0.58) TDP1ALDH1A1LMNASLC15A2FFAR3
SCHEMBL15455713 0.78 ALDH1A1 (0.50) TDP1ALDH1A1LMNASLC15A2TRPA1
SCHEMBL8519589 0.78 TDP1 (0.50) TDP1ALDH1A1LMNASLC15A2GRIK1
SCHEMBL4342888 0.78 ALDH1A1 (0.50) TDP1ALDH1A1LMNASLC15A2TRPA1
SCHEMBL9569276 0.77 ALDH1A1 (0.39) TDP1ALDH1A1
SCHEMBL6523715 0.77 ALDH1A1 (0.39) TDP1ALDH1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473152-B1 COMPOSITION COMPRISING A HYDROPHOBIC DYE, A SPECIFIC MINERAL AND/OR ORGANIC ALKALINE AGENT, A SPECIFIC COMPOUND (I) AND A SPECIFIC ORGANIC COMPOUND (II), AND USE THEREOF IN DYEING OREAL (FR) 2020-03-18 EP claimed
CN-102596156-A Composition comprising a hydrophobic dye, a specific mineral and/or organic alkaline agent, a specific compound (i) and a specific organic compound (ii), and use thereof in dyeing OREAL 2012-07-18 CN claimed
EP-0367132-B1 Light-sensitive composition BASF AG (DE) 1997-04-02 EP claimed
US-20230398226-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11833213-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-22 US disclosed
EP-2473152-B1 COMPOSITION COMPRISING A HYDROPHOBIC DYE, A SPECIFIC MINERAL AND/OR ORGANIC ALKALINE AGENT, A SPECIFIC COMPOUND (I) AND A SPECIFIC ORGANIC COMPOUND (II), AND USE THEREOF IN DYEING OREAL (FR) 2020-03-18 EP disclosed
CN-109890796-A Weeding pyridazinone compound 先正达参股股份有限公司 2019-06-14 CN disclosed
CN-103980103-B PHENOLIC COMPOUND, EPOXY RESIN, EPOXY RESIN COMPOSITION, PREPREG, AND CURED PRODUCT THEREOF 日本化药株式会社 2017-04-12 CN disclosed
CN-103764653-B As compound and the composition of c-Kit kinase inhibitor IRM LLC (BM) 2015-12-02 CN disclosed
US-20150147309-A1 ALLOSTERIC CHAPERONES AND USES THEREOF CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2015-05-28 US disclosed
US-20120004442-A1 SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS WELLSTAT THERAPEUTICS CORPORATION (US) 2012-01-05 US disclosed
WO-2011075498-A1 ONE-COMPONENT, AMBIENT CURABLE WATERBORNE COATING COMPOSITIONS, RELATED METHODS AND COATED SUBSTRATES PPG INDUSTRIES OHIO, INC. (US) 2011-06-23 WO disclosed
US-20110151128-A1 ONE-COMPONENT, AMBIENT CURABLE WATERBORNE COATING COMPOSITIONS, RELATED METHODS AND COATED SUBSTRATES PPG INDUSTRIES OHIO, INC. (US) 2011-06-23 US disclosed
US-20100160392-A1 HISTONE DEACETYLASE INHIBITORS QUEEN MARY & WESTFIELD COLLEGE (GB) 2010-06-24 US disclosed
WO-2010053910-A1 SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS WELLSTAT THERAPEUTICS CORPORATION (US) 2010-05-14 WO disclosed
US-20090309060-A1 Additives for Electrolyte Solution and Electrolyte Solution OTSUKA CHEMICAL CO., LTD. (JP) 2009-12-17 US disclosed
CN-101479818-A Additive for electrolyte and electrolyte OTSUKA CHEMICAL CO LTD (JP) 2009-07-08 CN disclosed
US-4244690-A USING AN AQUEOUS ALKALI SOLUTION OF THIOUREA DIOXIDE IN THE PRESENCE OF A KETONE COMPOUND TOKAI DENKA KOGYO KABUSHIKI KAISHA (JP) 1981-01-13 US disclosed
US-3988468-A 7-Methoxy-6-thiatetracyclines and their preparation MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) 1976-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398226-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS FCGR3B, ALB, FCGR1A TDP1 4479/4885ALDH1A1 3164/4885LMNA 3451/4885
US-20120004442-A1 SYNTHESIS OF (PHENYLALKYLOXY)PHENYL-OXOBUTANOIC ACIDS PGD, HPD, MLYCD TDP1 3194/4885ALDH1A1 346/4885LMNA 2006/4885
US-20090309060-A1 Additives for Electrolyte Solution and Electrolyte Solution SLC9A1, SLC26A3, AQP1 TDP1 2723/4885ALDH1A1 342/4885LMNA 568/4885
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS FCGR3B, FCGR1A, FCGR2A TDP1 4714/4885ALDH1A1 4869/4885LMNA 3986/4885
US-11833213-B2 Compositions and methods for the treatment of viral infections FCGR3B, ALB, FCGR1A TDP1 4479/4885ALDH1A1 3164/4885LMNA 3451/4885
US-20100160392-A1 HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC4 TDP1 3241/4885ALDH1A1 2757/4885LMNA 2226/4885
US-20150147309-A1 ALLOSTERIC CHAPERONES AND USES THEREOF GAA, GBA3, GBA1 TDP1 1118/4885ALDH1A1 3294/4885LMNA 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.